ArticleScientific reports2026
High efficacy of an in-house antigen B ELISA for diagnosing human cystic echinococcosis compared with a commercial kit and a cell-free DNA assay.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic echinococcosis (CE) continues to pose a serious zoonotic health risk in endemic areas. Serodiagnosis, while commonly utilized, faces challenges such as antigenic variability and stage-dependent sensitivity. The purpose of this study was to develop and evaluate an in-house ELISA using the isolated 12-kDa subunit of Antigen B (AgB) from Echinococcus granulosus sensu stricto, as well as to compare its performance to that of a commercial ELISA kit and acell-free DNA (cfDNA)-based PCR test. The 12-kDa AgB component was isolated from sheep hydatid cyst fluid and used to create an in-house IgG ELISA. The diagnostic performance was tested using ROC analysis. A total of 51 surgically and CT-confirmed CE patients and 50 healthy controls were included. Plasma cfDNA was collected and amplified using PCR targeting the COX1 gene. Cohen's kappa and Spearman's correlation were used to determine agreement. The in-house 12-kDa AgB ELISA demonstrated a sensitivity of 90.2%, a specificity of 100%, and an AUC of 0.936. Similarly, the commercial ELISA kit showed a sensitivity of 92.2% and a specificity of 100%. For its part, cfDNA-PCR successfully identified 88.2% of cases and exhibited a specificity of 100%. There was excellent agreement between the in-house and commercial ELISA kits (κ = 0.878) and serological and molecular techniques (κ = 0.78-0.81). The in-house 12-kDa AgB ELISA is a highly reliable and cost-effective diagnostic tool for CE, with performance equivalent to commercial ELISA kits and cfDNA-PCR assays. Future work should prioritize developing standardized recombinant subunits to improve the reliability and accessibility of AgB-based diagnostics in endemic areas. Moreover, direct cyst-tissue DNA warrants evaluation as a more sensitive and stable template for molecular confirmation, potentially overcoming limitations of serological and plasma cfDNA approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.